The following article is from HYBT, written by HYBT.

Big news:

Recently, two PCT international applications led by HYBT-R&D Team under HMI Group were authorized in Europe. Up to now, HMI Group has obtained six PCT international patents for biomedicine.

Authorized international patent this time:

"Use of cannabidiol in preparation of anti-influenza drugs (PCT/CN 2017/09956)"; "A composition containing cannabidiol and/or hypocannabidiol and its application in treating dysmenorrhea (PCT/CN2018/100835)".

Cannabidiol, extracted from hemp, a natural plant, has anti-inflammatory, analgesic, anxiolytic, anticonvulsant and neuroprotective effects, but has no psychoactive effects. Through in-depth exploration and research on the non-toxic active ingredients of industrial hemp with cannabidiol (CBD) as the core, and screening of different indications, HMI Group found that cannabidiol has remarkable efficacy in inhibiting influenza virus and RNA polymerase of influenza virus, and preventing and treating influenza. This important discovery filled the international research gap in this field.

Similarly, the combination of cannabidiol and/or hypocannabidiol in treating dysmenorrhea is also based on the anti-inflammatory and analgesic effects of cannabidiol. HMI Group's dysmenorrhea patent overcomes the defects of CBD in the prior art, such as inability to absorb quickly, inability to administer drugs continuously, and alcohol content, so that CBD can treat dysmenorrhea more effectively.

HMI Group has been deeply involved in the research and development of the medicinal value of the nontoxic active ingredients of industrial hemp, and constantly innovated. It has discovered the potential therapeutic effect of cannabinoids in the exploration experiments of various indications including rare diseases, and attached great importance to the protection of intellectual property rights, and has made patent layout all over the world. At present, which will surely form technical barriers in the future competition in the field of industrial hemp pharmacy. To realize HMI Group's vision of "devoting itself to becoming a world leader in the industrial hemp industry".